About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our laboratory, in the Neuromuscular Disorders Unit of the Neurology Service, has a twenty-year history of clinical care and research into amyotrophic lateral sclerosis (ALS) and other motor neurone diseases (hereditary, spastic paraplegia, post-polio syndrome, Hirayama disease, spinal muscular atrophy), myasthenia gravis, genetically determined myopathies, and peripheral neuropathies. Our main lines of research focus on the molecular mechanisms of amyotrophic lateral sclerosis and how genetic mutations in family ELA predispose or modify genetic factors. We also look for effective biomarkers in blood and in cerebrospinal fluid that allow the evaluation of new medication.
In our main research line, clinical/genetic characterization of familial forms of ALS, a Spanish/Italian collaboration evaluated a possible phenotype/genotype correlation and sought a founder effect in four Mediterranean families (3 Spanish and 1 Italian) carrying the p.I112M SOD1 mutation. This interesting study was motivated by the shared historical links between Catalonia and Sicily (Amyotroph Lateral Scler 2011;12:70-75).
IP: Josep Gamez Carbonell
In 2011, our group investigated the prevalence of FUS/TLS mutations in a Catalan familial ALS cohort previously studied for SOD1 in 2006. We identified the first two FUS/TLS families in Spain. One of the main conclusions is that FUS/TLS mutations are the second most common cause of FALS in our population (Amyotroph Lateral Scler 2011;12:118-123).
Our group joined ALSUntangled, a network of clinical experts in ALS providing an informed opinion about alternative and off-label treatments, about which they are frequently asked by patients attending their clinics. The goals for each investigation are to clarify what is on offer, its cost, the scientific and ethical basis of the ‘‘treatment’’, and the potential benefits and risks. In consequence, we published the following reports: Amyotroph Lateral Scler 2011;12:471-2, Amyotroph Lateral Scler 2011;12:389-91, Amyotroph Lateral Scler 2011;12:309-11, Amyotroph Lateral Scler 2011;12:235-7, Amyotroph Lateral Scler 2011;12:153-5.
IP: - Collaborators: Maria Salvadó Figueras, Consuelo Garcia Carmona, José Manuel Vidal Taboada, Javier Joaquín Sotoca Fernández, Arnau Llauradó Gayete, Daniel Sánchez-Tejerin San José, Laura Zalba Jadraque, Carmen Landabaso Roquero Funding agency: AGAUR no fer servir-correcte 4301-37 Funding: 0.01 Reference: 2021 SGR 01121 Duration: 01/01/2022 - 31/12/2024
IP: José Manuel Vidal Taboada Collaborators: Arnau Llauradó Gayete, Miriam Izquierdo Sans Funding agency: Fundació Institut de Recerca HUVH Funding: 117000 Reference: HUVH/BPFSE_G-D/2022/LLAURADÓ Duration: 14/06/2022 - 13/06/2024
IP: Josep Quer Sivila Collaborators: Sergi Colomer Castell, Marta Ibañez Lligoña, Lluís Viladomiu Catà, Damir Garcia Cehic, Maria Piñana Moro, Pablo Gabriel Medina, Arnau Llauradó Gayete, Carolina Campos Martinez, Alejandra Gonzalez Sánchez Funding agency: Instituto de Salud Carlos III Funding: 292820 Reference: PI22/00258 Duration: 01/01/2023 - 31/12/2025
IP: José Manuel Vidal Taboada Collaborators: Maria Jose Herrero Mata, Maria Salvadó Figueras, Josep Gamez Carbonell, Consuelo Garcia Carmona, Laura Zalba Jadraque, Arnau Llauradó Gayete Funding agency: Instituto de Salud Carlos III Funding: 117370 Reference: PI19/00593 Duration: 01/01/2020 - 30/06/2024
PMID: 35166156 Journal: CEPHALALGIA Year: 2022 Reference: Cephalalgia. 2022 Jul;42(8):804-809. doi: 10.1177/03331024211068074. Epub 2022 Feb 15. Impact factor: 6.295 Publication type: Paper in international publication Authors: Pozo-Rosich, Patricia; de Lorenzo, Inigo; Garcia-Azorin, David; Layos-Romero, Almudena; Porta-Etessam, Jesus; Membrilla, Javier A; Caronna, Edoardo; Gonzalez-Martinez, Alicia; Mencia, Alvaro Sierra; Segura, Tomas et al. DOI: 10.1177/03331024211068074
PMID: 35524016 Journal: NEUROLOGICAL SCIENCES Year: 2022 Reference: Neurol Sci. 2022 May 6. pii: 10.1007/s10072-022-06102-y. doi: 10.1007/s10072-022-06102-y. Impact factor: 3.307 Publication type: Paper in international publication Authors: Salvado, Maria, Caro, Jose Luis, Rudilla, Francesc, Zalba-Jadraque, Laura, Lopez, Eva, Sanjuan, Elia, Gamez, Josep, Vidal-Taboada, Jose Manuel, Garcia, Cecilia et al. DOI: 10.1007/s10072-022-06102-y
PMID: 35332927 Journal: REVISTA DE NEUROLOGIA Year: 2022 Reference: Rev Neurol. 2022 Apr 1;74(7):232-241. doi: 10.33588/rn.7407.2021495. Impact factor: 0.87 Publication type: Review in national publication Authors: Llaurado, A, Sanchez-Tejerina, D, Vidal-Taboada, J M, Salvado, M, Sotoca, J, Juntas-Morales, R et al. DOI: 10.33588/rn.7407.2021495
PMID: 35296683 Journal: npj Parkinsons Disease Year: 2022 Reference: NPJ Parkinsons Dis. 2022 Mar 16;8(1):27. doi: 10.1038/s41531-022-00290-2. Impact factor: 8.651 Publication type: Paper in international publication Authors: Rabaneda-Lombarte, Neus, Vidal-Taboada, Jose Manuel, Valente, Tony, Ezquerra, Mario, Fernandez-Santiago, Ruben, Marti, Maria Jose, Compta, Yaroslau, Saura, Josep, Sola, Carme et al. DOI: 10.1038/s41531-022-00290-2
PMID: 34170003 Journal: REVISTA DE NEUROLOGIA Year: 2021 Reference: Rev Neurol. 2021 Jul 1;73(1):10-16. doi: 10.33588/rn.7301.2021042. Impact factor: 0.87 Publication type: Paper in national publication Authors: Ballve, A, Llaurado, A, Palasi, A, Quintana, M, Lainez, E, Raguer, N, Juntas-Morales, R, Martinez-Saez, E et al. DOI: 10.33588/rn.7301.2021042
PMID: 33875301 Journal: NEUROLOGIA Year: 2021 Reference: Neurologia (Engl Ed). 2021 Apr 16. pii: S0213-4853(21)00053-0. doi: 10.1016/j.nrl.2021.02.014. Impact factor: 3.109 Publication type: Paper in national publication Authors: Llaurado, A, Quintana, M, Fonseca, E, Abraira, L, Toledo, M, Requena, M, Olive, M, Ballve, A, Campos, D, Sueiras, M et al. DOI: 10.1016/j.nrl.2021.02.014
PMID: 33576710 Journal: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Year: 2021 Reference: Amyotroph Lateral Scler Frontotemporal Degener. 2021 Nov;22(7-8):505-507. doi: 10.1080/21678421.2021.1883669. Epub 2021 Feb 12. Impact factor: 4.092 Publication type: Paper in international publication Authors: Pageot, Nicolas, Juntas-Morales, Raul, Alphandery, Sebastien, Camu, William, De La Cruz, Elisa, Esselin, Florence et al. DOI: 10.1080/21678421.2021.1883669
PMID: 31781168 Journal: Frontiers in Genetics Year: 2019 Reference: Front Genet. 2019 Nov 8;10:1109. doi: 10.3389/fgene.2019.01109. eCollection 2019. Impact factor: 3.517 Publication type: Paper in international publication Authors: Gamez, Josep, Morales, Miguel, Salvado, Maria, Vidal-Taboada, Jose Manuel, Garcia, Cecilia, Syriani, Enrique et al. DOI: 10.3389/fgene.2019.01109
PMID: 31645906 Journal: Oncotarget Year: 2019 Reference: Oncotarget. 2019 Oct 8;10(56):5871-5887. doi: 10.18632/oncotarget.27232. eCollection 2019 Oct 8. Impact factor: 0 Publication type: Paper in international publication Authors: Alvarez-Palomo, Belen, Barrot-Feixat, Carme, Sarret, Helena, Requena, Jordi, Pau, Montserrat, Vidal-Taboada, Jose-Manuel, Oliva, Rafael, Ballesca, Josep-Lluis, Edel, Michael J, Mezquita-Pla, Jovita et al. DOI: 10.18632/oncotarget.27232
PMID: 30382133 Journal: Scientific Reports Year: 2018 Reference: Sci Rep. 2018 Oct 31;8(1):16096. doi: 10.1038/s41598-018-34412-9. Impact factor: 4.122 Publication type: Paper in international publication Authors: Pulido-Salgado, Marta, Vidal-Taboada, Jose M, Barriga, Gerardo Garcia-Diaz, Sola, Carme, Saura, Josep et al. DOI: 10.1038/s41598-018-34412-9
PhD student: Maria Salvadó Figueras Director/s: Josep Gamez Carbonell, José Manuel Vidal Taboada University: Universidad Autònoma de Barcelona Year: 2020
